Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts

Cancer

Volumn 75, Issue 7 S, 1995, Pages 1850-1859

  di Sant'Agnese, P Anthony ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

APUD; neuroendocrine; paracrine; prostate; prostate cancer

Indexed keywords

BOMBESIN; BOMBESIN ANTAGONIST; CHROMOGRANIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIN RELEASING PEPTIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON; NEUROPEPTIDE; ONCOPROTEIN; PARATHYROID HORMONE RELATED PROTEIN; RC 3095; SEROTONIN; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; SUBSTANCE P ANTAGONIST; VAPREOTIDE;

APUD CELL; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TUMOR DIFFERENTIATION;

EID: 0028945091     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950401)75:7+<1850::AID-CNCR2820751615>3.0.CO;2-4     Document Type: Article

References (77)

1. Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic, and therapeutic implications
2. Human prostatic endocrine‐paracrine (APUD) cells: distributional analysis with a comparison of serotonin and neuron‐specific enolase immunoreactivity and silver stains
3. Peptide‐hormone and serotonin‐immunoreactive cells in normal and hyperplastic prostate glands
4. Zur frage der endokrin der menschlichen vorsteherdruse
5. The cytochemistry and ultrastructure of polypeptide hormone‐producing cells of the APUD series and the embryologic, physiologic, and pathologic implications of the concepts
6. Morphological and immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood
7. The neuroendocrine cell population of the human prostate gland
8. Age‐related distribution of endocrine cells in the human prostate: a quantitative study
9. Relationship of neuroendocrine cells of prostate and serotonin to benign prostate hyperplasia
10. Age‐elated changes in the neuroendocrine (endocrine‐paracrine) cell population and the serotonin content of the guinea pig prostate
11. Endocrine‐paracrine cells if the prostate and prostatic urethra;an ultrastructural study
12. Human prostate carcinoma causes hypercalcemia in athymic nude mice and produces a factor with parathyroid hormone‐like bioactivity
13. Immunohistochemical localization of parathyroid hormone‐related protein in human prostate cancer
14. Parathyroid hormone‐related protein is expressed by prostatic neuroendocrine cells
15. Detection of parathyroid hormone‐related protein mRNA in neuroendocrine cells of the prostate gland by in situ hybridization with exon specific probes [abstract]
16. Prostatic neuroendocrine cell products in human seminal plasma [abstract]
17. Parathyroid hormone‐related protein: a potential autocrine growth Regulator in human prostate cancer cell lines
18. Parathyroid hormone‐related protein: evidence for isoform‐ and tissue‐specific posttranslational processing
19. Parathyroid hormone‐related protein as a prohormone posttranslational processing and receptor interactions
20. Parathyroid hormone‐related protein (PTHrP) gene expression in solid tumours associated with normocalcaemia and hypercalcaemia
21. The parathyroid hormone‐related protein associated with malignancy is secreted by neuroendocrine tumors
22. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an “endocrine marker.”
23. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate
24. Chromogranin A peptide‐specific antisera and high‐performance size exclusion chromotography demonstrate amino‐terminal and carboxy‐terminal fragments of native molecule in human cell lines (43712)
25. Novel peptides from adrenomedullary chromaffin vesicles
26. Overexpression of human epidermal growth factor receptor and c‐erbB‐2 by neuroendocrine cells in normal prostatic tissue
27. Immunohistochemical localization of epidermal growth factor receptor and myc oncogene product in human placenta: implication for throphoblast proliferation and differentiation
28. Isolation and structure of urogastrone and the relationship to epidermal growth factor
29. Regulation of parathyroid hormone‐like peptide in cultured normal human keratinocytes: effect growth factors and I 25 dihydroxyvitamin D3 on gene expression and secretion
30. Parathyroid hormone‐related protein production by primary cultures of mammary epithelial cells
31. Increase in epidermal growth factor receptor and its mRNA levels by parathyroid hormone (1‐34) and parathyroid hormone‐related protein (1‐34) during differentiation of human trophoblast cells in culture
32. Expression of the c‐erbB‐2 (HER‐2/neu) oncoprotein in human prostatic carcinoma
33. p53, C‐erbB‐2 and the epidermal growth factor receptor in the benign and malignant prostate
34. Neurotensin stimulates growth of small intestine in rats
35. Expression of neurotensin in endocrine tumors
36. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal on human prostate cancer
37. B‐endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells
38. Presence of calcitonin‐like immunoreactivity (iCT) in human prostate gland: Evidence for iCT secretion by cultured prostate cells
39. 2+ Transients
40. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma
41. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate
42. Prostatic‐specific antigen and prostate‐specific acid phosphatase in neuroendocrine cells of prostate cancer
43. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP
44. Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate
45. Endocrine‐paracrine cell types in prostate cancer are postmitotic cells
46. BCL‐2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell
47. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue
48. Androgen receptor immunostaining and its tissue distribution in formalin‐fixed, paraffin‐embedded sections after microwave treatment
49. Distribution and androgen receptor status of neuroendocrine cells in the prostate
50. Androgen receptor status in endocrine‐paracrine cell types of the normal, hyperplastic, and neoplastic human prostate
51. Do neuroendocrine cells in human prostate cancer express androgen receptor?
52. Neuro‐endocrine cells: a new prognostic parameter in prostate cancer
53. Hormone resistant prostatic adenocarcinoma: an elevation of prognostic factors in pre‐ and post‐treatment specimens
54. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma
55. Paneth cell‐like change and small cell carcinoma of the prostate: two divergent forms of prostatic neuroendocrine differentiation
56. Paneth cell‐like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study
57. Mucin‐secreting adenocarcinoma of the prostate with neuroendocrine differentiation and Paneth‐like cells
58. Paneth cell‐like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases
59. Paneth cell‐like metaplasia of the prostate gland
60. Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation
61. Chemotherapy for small cell carcinoma of prostatic origin
62. Small cell carcinoma of prostate effectiveness of hormonal versus chemotherapy
63. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients
64. Modulation of oncogene and tumor suppressor gene expression in a hamster mode of chronic lung injury with varying degrees of pulmonary neuroendocrine cell hyperplasia
65. Neurotransmitters as growth regulatory signals: role of receptors and second messengers
66. Somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 inhibit the growth of androgen‐independent DU‐145 human prostate cancer line in rude mice
67. Antagonists of bombesin/gastrin‐releasing peptide as adjuncts to agonists of luteinizing hormone‐releasing hormone in the treatment of experimental prostate cancer
68. Synergistic effects of bombesin and epidermal growth factor on cancers (gastrin‐releasing peptide/bombesin antagonist RC‐3095/hamster buccal cheek pouch/dimethylbenzanthracene/receptor regulation)
69. 6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC 150
70. Expression of p53 protein in prostate cancers of different histologic types
71. Dopamine activation of an orphan of the steroid receptor superfamily
72. Dopaminergic and ligand‐independent activation of steroid hormone receptors
73. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC‐160 on the invasive capacity of human prostatic carcinoma cells
74. Medical treatment of neuroendocrine tumors
75. Therapeutic use and perspectives of synthetic peptides in oncology
76. Broad spectrum neuropeptide antagonists inhibit growth of small cell lung cancer in vivo